Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma

Results of a randomized phase II study

C. Pozzo, Carlo Barone, J. Szántó, E. Padi, C. Peschel, J. Bükki, V. Gorbunova, V. Valvere, J. Zaluski, M. Biakhov, E. Zuber, C. Jacques, R. Bugat

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Background: To identify the most effective of two combinations, irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) and irinotecan/cisplatin, in the treatment of advanced gastric cancer, for investigation in a phase III trial. Patients and methods: Patients were randomized to receive irinotecan [80 mg/m2 intravenously (i.v.)], FA (500 mg/m2 i.v.) and a 22-h infusion of 5-FU (2000 mg/m2 i.v.), weekly for 6 weeks with a 1-week rest, or irinotecan (200 mg/m2 i.v. and cisplatin (60 mg/m2 i.v.), on day 1 for 3 weeks. Results: A total of 115 patients were eligible for analysis in the per-protocol population. The overall response rate in the irinotecan/5-FU/FA arm (n = 59) was 42.4%, with a complete response rate of 5.1%. Corresponding figures for the irinotecan/cisplatin arm (n = 56) were 32.1% and 1.8%, respectively. The median time to progression was 6.5 months (irinotecan/5-FU/FA) and 4.2 months (irinotecan/cisplatin) (P

Original languageEnglish
Pages (from-to)1773-1781
Number of pages9
JournalAnnals of Oncology
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2004

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Cisplatin
Stomach
Adenocarcinoma

Keywords

  • 5-FU/FA
  • Advanced gastric cancer
  • Cisplatin
  • Irinotecan
  • Phase II

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma : Results of a randomized phase II study. / Pozzo, C.; Barone, Carlo; Szántó, J.; Padi, E.; Peschel, C.; Bükki, J.; Gorbunova, V.; Valvere, V.; Zaluski, J.; Biakhov, M.; Zuber, E.; Jacques, C.; Bugat, R.

In: Annals of Oncology, Vol. 15, No. 12, 12.2004, p. 1773-1781.

Research output: Contribution to journalArticle

Pozzo, C, Barone, C, Szántó, J, Padi, E, Peschel, C, Bükki, J, Gorbunova, V, Valvere, V, Zaluski, J, Biakhov, M, Zuber, E, Jacques, C & Bugat, R 2004, 'Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study', Annals of Oncology, vol. 15, no. 12, pp. 1773-1781. https://doi.org/10.1093/annonc/mdh473
Pozzo, C. ; Barone, Carlo ; Szántó, J. ; Padi, E. ; Peschel, C. ; Bükki, J. ; Gorbunova, V. ; Valvere, V. ; Zaluski, J. ; Biakhov, M. ; Zuber, E. ; Jacques, C. ; Bugat, R. / Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma : Results of a randomized phase II study. In: Annals of Oncology. 2004 ; Vol. 15, No. 12. pp. 1773-1781.
@article{3525b621d87d4e00a11b36ceeaf4817d,
title = "Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study",
abstract = "Background: To identify the most effective of two combinations, irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) and irinotecan/cisplatin, in the treatment of advanced gastric cancer, for investigation in a phase III trial. Patients and methods: Patients were randomized to receive irinotecan [80 mg/m2 intravenously (i.v.)], FA (500 mg/m2 i.v.) and a 22-h infusion of 5-FU (2000 mg/m2 i.v.), weekly for 6 weeks with a 1-week rest, or irinotecan (200 mg/m2 i.v. and cisplatin (60 mg/m2 i.v.), on day 1 for 3 weeks. Results: A total of 115 patients were eligible for analysis in the per-protocol population. The overall response rate in the irinotecan/5-FU/FA arm (n = 59) was 42.4{\%}, with a complete response rate of 5.1{\%}. Corresponding figures for the irinotecan/cisplatin arm (n = 56) were 32.1{\%} and 1.8{\%}, respectively. The median time to progression was 6.5 months (irinotecan/5-FU/FA) and 4.2 months (irinotecan/cisplatin) (P",
keywords = "5-FU/FA, Advanced gastric cancer, Cisplatin, Irinotecan, Phase II",
author = "C. Pozzo and Carlo Barone and J. Sz{\'a}nt{\'o} and E. Padi and C. Peschel and J. B{\"u}kki and V. Gorbunova and V. Valvere and J. Zaluski and M. Biakhov and E. Zuber and C. Jacques and R. Bugat",
year = "2004",
month = "12",
doi = "10.1093/annonc/mdh473",
language = "English",
volume = "15",
pages = "1773--1781",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma

T2 - Results of a randomized phase II study

AU - Pozzo, C.

AU - Barone, Carlo

AU - Szántó, J.

AU - Padi, E.

AU - Peschel, C.

AU - Bükki, J.

AU - Gorbunova, V.

AU - Valvere, V.

AU - Zaluski, J.

AU - Biakhov, M.

AU - Zuber, E.

AU - Jacques, C.

AU - Bugat, R.

PY - 2004/12

Y1 - 2004/12

N2 - Background: To identify the most effective of two combinations, irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) and irinotecan/cisplatin, in the treatment of advanced gastric cancer, for investigation in a phase III trial. Patients and methods: Patients were randomized to receive irinotecan [80 mg/m2 intravenously (i.v.)], FA (500 mg/m2 i.v.) and a 22-h infusion of 5-FU (2000 mg/m2 i.v.), weekly for 6 weeks with a 1-week rest, or irinotecan (200 mg/m2 i.v. and cisplatin (60 mg/m2 i.v.), on day 1 for 3 weeks. Results: A total of 115 patients were eligible for analysis in the per-protocol population. The overall response rate in the irinotecan/5-FU/FA arm (n = 59) was 42.4%, with a complete response rate of 5.1%. Corresponding figures for the irinotecan/cisplatin arm (n = 56) were 32.1% and 1.8%, respectively. The median time to progression was 6.5 months (irinotecan/5-FU/FA) and 4.2 months (irinotecan/cisplatin) (P

AB - Background: To identify the most effective of two combinations, irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) and irinotecan/cisplatin, in the treatment of advanced gastric cancer, for investigation in a phase III trial. Patients and methods: Patients were randomized to receive irinotecan [80 mg/m2 intravenously (i.v.)], FA (500 mg/m2 i.v.) and a 22-h infusion of 5-FU (2000 mg/m2 i.v.), weekly for 6 weeks with a 1-week rest, or irinotecan (200 mg/m2 i.v. and cisplatin (60 mg/m2 i.v.), on day 1 for 3 weeks. Results: A total of 115 patients were eligible for analysis in the per-protocol population. The overall response rate in the irinotecan/5-FU/FA arm (n = 59) was 42.4%, with a complete response rate of 5.1%. Corresponding figures for the irinotecan/cisplatin arm (n = 56) were 32.1% and 1.8%, respectively. The median time to progression was 6.5 months (irinotecan/5-FU/FA) and 4.2 months (irinotecan/cisplatin) (P

KW - 5-FU/FA

KW - Advanced gastric cancer

KW - Cisplatin

KW - Irinotecan

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=19944424421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944424421&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh473

DO - 10.1093/annonc/mdh473

M3 - Article

VL - 15

SP - 1773

EP - 1781

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -